About: Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 04 April 2005

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2005 (fr) наукова стаття, опублікована у 2005 (uk) im April 2005 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'abril de 2005 (ast) scientific article published on 04 April 2005 (en)
publication date	wds:Q57222503-EFB55AD0-9788-470B-BAB6-E1F31D3FD650
publication date	2005-04-04 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57222503-36D49C4E-1ECD-439D-8E71-4EABE5097695
language of work or name	English
cites work	wds:Q57222503-0B7D36B4-5527-4E84-9EB8-BAB16DD03195 wds:Q57222503-619BDA8D-D612-4740-9DDD-318CB9A88FE6 wds:Q57222503-90D3F3C8-DCE0-4609-A306-9C0955B2487B wds:Q57222503-9648CDEB-6270-444E-9743-F7FCA02B4CA9
cites work	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia Renal osteodystrophy: management of hyperphosphataemia
author name string	wds:Q57222503-2F4AF10E-347C-44DA-B9D2-4138D4DC1B33 wds:Q57222503-50A54520-FD0F-4167-A00E-1A735BC2D731 wds:Q57222503-512019B2-0F8F-4F5B-BBE3-25A4BD75D199 wds:Q57222503-807D3D04-677F-4665-95F2-BBF4E7AFE1A4 wds:Q57222503-85C6BF17-E9C3-4801-8310-C6BC816660A2 wds:Q57222503-8F7C0023-722F-41F6-B08A-B0E470BE6E57 wds:Q57222503-940BA7F3-D826-4461-B9A1-BBED8AC21067 wds:Q57222503-D7781B67-77B8-49CB-BEF1-704765A5B604
author name string	R Schmieder B Maes E Mohamed J Vanwalleghem G Asmus A Vosskuhler R Jamar W Backs
rdfs:label	Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate (en) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate (nl)
skos:prefLabel	Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate (en) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate (nl)
name	Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate (en) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate (nl)
author	wds:Q57222503-EB992080-111C-4552-BB2F-8C206742CCCB
author	Alastair J Hutchison
title	wds:Q57222503-61A815FD-11BB-4A07-9911-0884DDF22F31
title	Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate (en)
page(s)	wds:Q57222503-EB46F678-D9DD-45F8-952D-5ED20FA79833
page(s)	c8-19
instance of	wds:Q57222503-A768B027-5EB2-482B-88B9-7D895658EBE4
instance of	scholarly article
main subject	wds:Q57222503-CDD16F95-AF36-475B-AEB5-BD0E962D19D6
main subject	lanthanum
PubMed ID	wds:Q57222503-3CC0A335-80A0-4221-88C8-964AC667F91A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15809508
PubMed ID	15809508
published in	wds:Q57222503-16FFC546-A34B-4E76-BE5B-43AE82122591
published in	The Nephron Journals
issue	wds:Q57222503-CBA10225-13F9-4AEA-8D84-31651B315D8D
volume	wds:Q57222503-299E42DA-9C67-4514-BD34-894C160E6641
issue	1
volume	100
DOI	wds:Q57222503-48DE0679-FBA2-44E9-936B-EF3D873EACE2
DOI	http://dx.doi.org/10.1159/000084653
DOI	10.1159/000084653
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57222503
is cites work of	Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability Management of hyperphosphataemia in chronic kidney disease-challenges and solutions Clinical pharmacokinetics of the phosphate binder lanthanum carbonate Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment Pharmacology, efficacy and safety of oral phosphate binders The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium Acute functional neurotoxicity of lanthanum(III) in primary cortical networks Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model. Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate. Oral phosphate binders The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence Lanthanum carbonate. Current treatment options in secondary renal hyperparathyroidism Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate A new era in phosphate binder therapy: what are the options? Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis Hyperphosphataemia: treatment options Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients Patient education for phosphorus management in chronic kidney disease Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. Hyperphosphatemia Management in Patients with Chronic Kidney Disease Phosphate binders: new products and challenges Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs Treatment options for hyperphosphatemia in feline CKD: what's out there? Therapeutic use of the phosphate binder lanthanum carbonate

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software